磷[32P]酸铬(Chromic Phosphate P-32)-_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

Phosphocol P32

靶点-

作用机制-

治疗领域

肿瘤

在研适应症-

非在研适应症

肿瘤

原研机构-

在研机构-

非在研机构

Curium US Holdings LLC

最高研发状态(全球)撤市

首次获批日期(全球)

美国 (1974-09),

肿瘤

最高研发状态(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

100 项与磷[32P]酸铬相关的专利（医药）

登录后查看更多信息

28

项与磷[32P]酸铬相关的文献（医药）

2023-12-01·Drug delivery

Design and evaluation of ³²P-labeled hydroxyapatite nanoparticles for bone tumor therapy.

Article

作者: Dongliang Zhai ; Yumei Wang ; Songke Yu ; Jiren Zhou ; Jia Song ; Shilei Hao ; Xiaoliang Chen

The clinical diagnosis and treatment of malignant bone tumors are still major clinical challenges due to their high incidence are difficulty. Targeted therapies have become a critical approach to treat bone tumors. In recent years, radiopharmaceuticals have been used widely and have shown potent and efficient results in treating bone tumors, among which ³²P and the labeled radiopharmaceuticals play an essential role. In this study, the ³²P-labeled hydroxyapatite (HA) was prepared through chemical synthesis (³²P-Hap) and physical adsorption (³²P-doped-Hap). The in vitro stability of ³²P-labeled HA was analyzed to assess the superiority of the new-found chemical synthesis. The radiolabeling yield and stability of chemical synthesis (97.6 ± 0.5%) were significantly improved compared with physical adsorption (92.7 ± 0.4%). Furthermore, the CT results corroborate that ³²P-Hap (100 μCi) +DOX group has the highest tumor suppression rate and can effectively reduce bone destruction. The results corroborate the effectiveness of the chemical synthesis and validate the application of ³²P-Hap in bone tumors. Therefore, ³²P-Hap (100 μCi) + DOX may be an effective strategy for bone metastasis treatments.

2015-12-01·Neuro-oncology practice

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

Article

作者: Paul D Brown ; S Keith Anderson ; Xiomara W Carrero ; Brian P O'Neill ; Caterina Giannini ; Eva Galanis ; Sunjay A Shah ; Ross A Abrams ; Walter J Curran ; Jan C Buckner ; Edward G Shaw

BACKGROUND:

Pilocytic astrocytoma is a rare tumor in adults. This report is of a prospective clinical trial with long-term follow-up.

METHODS:

Between 1986 and 1994, 20 eligible adults with supratentorial pilocytic astrocytomas were enrolled in a prospective intergroup trial of radiotherapy (RT) after biopsy (3 patients) or observation after gross (11 patients) or subtotal (6 patients) resection.

RESULTS:

At the time of analysis (median follow-up, 20.8 years), 2 patients (10%) have died and 18 patients (90%) are alive. Neurologic and cognitive function were stable or improved over time for the majority of patients. No toxic effects of treatment or malignant transformations have been recorded at last follow-up. For the entire cohort the 20-year time to progression and overall survival rates are 95% and 90% respectively. The cause of death (2.2 and 16.1 years after enrollment) in both patients was unrelated to tumor although both were biopsy-only patients. One subtotally resected tumor progressed 1 month after enrollment requiring P³² injection into an enlarging cyst. Because of further progression this patient required RT 18 months later. This patient is alive without evidence of progression 18 years after RT.

CONCLUSION:

The long-term follow-up results of this prospective trial confirm that adults with pilocytic astrocytomas have a favorable prognosis with regard to survival and neurologic function. Close observation is recommended for adults with pilocytic astrocytomas, reserving RT for salvage, as the majority remain stable after gross or subtotal resection and no adjuvant therapy.

2012-03-01·Cancer Biotherapy and Radiopharmaceuticals4区 · 医学

Safety Evaluation of ³²P-Chromic Phosphate-Poly L Lactic Acid Particles Interstitially Implanted into Livers of Beagle Dogs

4区 · 医学

Article

作者: Liu, Lu ; Huang, Peilin ; Nie, Qi ; Qi, Benzhong ; Wu, Qinghua ; Gao, Hailin ; Yang, Zexuan ; Chen, Daming

AIMS:

The aim of this study was to investigate the safety and toxicity of biodegradable (32)P-chromic phosphate-poly L lactic acid ((32)P-CP-PLLA) particles interstitially implanted into Beagle dog livers.

METHODS:

Eighteen healthy Beagle dogs were randomly divided into 6 groups (n=3), and were treated with drugs of different formulations or doses, as well as controls. At different time points after surgery, the experimental dogs were weighed. Detection of indicators of blood chemistry and liver fibrosis, SPECT bremsstrahlung imaging, computed tomography, histological examination, continuous blood measurement, and counting of urine and fecal radioactivity were performed for these dogs.

RESULTS:

SPECT imaging showed that after implantation of radioactive particles into livers, radioactivity continuously accumulated in the implanted sites, while no radioactivity imaging was found in the nonimplantation sites. The mean absorbance doses in the implantation sites were 89.8-178.7 Gy. Local spherical lesions were observed in tissues. The average effective half-life time of (32)P-CP-PLLA was 11.8 days. Within 4 weeks after surgery, slight or moderate swelling and degradation of liver cells were detected, while in 8 weeks after surgery, they are normal. For the blood chemistry, liver fibrosis, and other indicators, no significant differences were found between the control groups and particle implantation groups (F=1.378, p=0.232).

CONCLUSIONS:

(32)P-CP-PLLA particles have advantages including good targeting, immobile, being degradable in vivo, easy to be protected, and so on. It is suitable for treating solid tumors with blood supply. (32)P-CP-PLLA particles are a kind of safe, novel, radioactive implantation drug.

研发状态

适应症	最高研发状态	国家/地区	公司
肿瘤	撤市	美国更多	Curium US Holdings LLC 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2007 AI 标引	-	难治性头颈癌	14	Intralesional 32-P chromic phosphate	繭簾網製齋夢夢膚壓鏇 = 積製憲構壓製醖艱積蓋鑰糧鹹製壓壓憲憲構積 (範製遞膚製顧鏇醖選膚 ) 更多	-	2007-06-20